linjc16/ctgov huggingface dataset:
Enhancement of Postocclusive Reactive Hyperaemia by Dipyridamole

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether dipyridamole enhances postocclusive reactive hyperaemia by increasing extracellular adenosine concentrations during ischemia and reperfusion. Furthermore we hypothesize that dipyridamole augments postocclusive reactive hyperaemia by increasing adenosine receptor stimulation.

Official Title
-----------------
Enhancement of Postocclusive Reactive Hyperaemia

Conditions
-----------------
Hyperemia, Hypoxia

Intervention / Treatment
-----------------
* Drug: dipyridamole
* Drug: caffeine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy volunteers between 18 and 50 years Exclusion Criteria: none specified

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: dipyridamole|nan|
|Drug: caffeine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| forearm blood flow |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adenosine, caffeine, dipyridamole
Incidence of Phantom Limb Pain and Method of Anesthesia After Lower Extremity Amputation

Study Overview
=================
Brief Summary
-----------------
Phantom limb pain (pain originating from where an amputated limb once was) is a common occurrence after lower extremity amputations, with some sources noting incidence to be as high as 60-80% six months after surgery. This pain can eventually subside, however, cases have been reported of incidence 10 years after surgery. This pain is not only physically detrimental, but can also be psychologically detrimental after a difficult to accept change in the body. Prior studies have been performed using regional anesthetic techniques (including spinals and epidurals) and different medications to attempt to reduce the incidence of phantom limb pain, however, the data have been mostly inconclusive. Of interest, prior studies have not addressed peripheral nerve blocks, a method of anesthesia/analgesia more commonly employed for amputations recently. The purpose of our retrospective study is to look at the incidence of phantom limb pain at our institution over a two year period to determine if peripheral nerve blocks result in a significantly reduced incidence compared to other techniques (spinal, epidural, general anesthesia only). In addition, there is little data on relation of reason for amputation and presence of preoperative neuropathy and incidence of phantom pain. As secondary endpoints, the investigators wish to investigate if certain reasons for amputation (trauma, peripheral vascular disease, diabetes, and others) and/or neuropathy lead to a higher incidence of phantom limb pain. The results of this study could impact future management of patients who are to receive amputations and may lead to further prospective studies on the topics involved.

Official Title
-----------------
Incidence of Phantom Limb Pain and Method of Anesthesia After Lower Extremity Amputation

Conditions
-----------------
Phantom Limb Pain

Intervention / Treatment
-----------------
* Procedure: Lower extremity amputation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who receive lower extremity amputation Exclusion Criteria: Death or incapacitating medical condition since surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| General Anesthesia only<br> | Procedure: Lower extremity amputation<br> <br> |
| Peripheral nerve block<br> | Procedure: Lower extremity amputation<br> <br> |
| spinal<br> | Procedure: Lower extremity amputation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Treatment of Foot and Leg Ulcers Using a Laser

Study Overview
=================
Brief Summary
-----------------
The investigators plan to do a retrospective chart review on patients who underwent laser treatment for their foot ulcer at the UT Southwestern wound clinic.

Detailed Description
-----------------
The investigators plan to do a retrospective chart review on patients who underwent laser treatment for their foot ulcer at the UT Southwestern wound clinic starting on May 17, 2018 to November 13, 2018. The investigators chose this date because that is the first time laser treatments were performed in the clinic. The investigators will collect the following data points: Ulcer etiology Ulcer location Prior ulcer treatment type and duration, and wound measurements/characteristics Wound size 4-6 weeks prior to laser treatment; at treatment time; and then each follow up measurement healed or x weeks eGFR Albumin Last A1c-Presence/absence of DM Amputation history Vascular status via ABI's Identify comorbidities Identify associated encounters in the patients such as complications (i.e. infection), related readmissions The investigators will identify this information from patient charts (EPIC EMR).

Official Title
-----------------
Treatment of Foot and Leg Ulcers Using a Laser

Conditions
-----------------
Diabetic Foot Ulcer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who underwent laser treatment for their foot ulcer at the UT Southwestern wound clinic starting on May 17, 2018 to November 13, 2018 Exclusion Criteria: not meeting inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improved healing rate to time to healing | Wounds assessed in this study will show significant improvement in wound characteristics after Erbium-YAG laser debridement(s). Improved healing rate to time to healing. | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decreased complications in diabetic foot ulcers, i.e. infection, hospital admission, amputation | Wounds assessed in this study will show significant improvement in wound characteristics after Erbium-YAG laser debridement(s). Decreased complications in diabetic foot ulcers, i.e. infection, hospital admission, amputation | 4 weeks |
Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes

Study Overview
=================
Brief Summary
-----------------
Examine red and white blood cells of PNH patients with bone marrow failure syndromes.

Official Title
-----------------
P06-001: (EX)Amination of (P)NH, by (L)Evel (O)f CD59 on (RE)d and White Blood Cells, in Bone Marrow Failure Syndromes

Conditions
-----------------
Hemoglobinuria

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 10 years of age. Has aplastic anemia, myelodysplastic syndromes or other bone marrow failure syndromes Exclusion Criteria: Has any condition that might interfere with the patient's participation

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PNH clone cells, Aplastic Anemia, AA, Myelodysplastic Syndromes, MDS, bone marrow failure syndromes, FLAER, Paroxysmal Nocturnal Hemoglobinuria
Swan-Ganz CCOmbo V for Obtaining an Optimal Depth of Right Internal Jugular Venous Catheter

Study Overview
=================
Brief Summary
-----------------
The investigators will perform a study to create formula for the optimal insertion depth of right internal jugular vein catheter.

Detailed Description
-----------------
Patients scheduled for cardiac surgery were studied.Determine the optimal insertion depth of right internal jugular vein catheter using Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V).The investigators measure the distance between the insertion point and the junction between right atrium and superior vena cava using Swan-Ganz CCOmbo V.

Official Title
-----------------
Swan-Ganz CCOmbo V for Obtaining an Optimal Depth of Right Internal Jugular Venous Catheter : A Prospective Observational Study

Conditions
-----------------
Insertion Depth of Central Venous Catheter

Intervention / Treatment
-----------------
* Device: Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient over 18 years of age undergoing mitral valve or/and tricuspid valve Surgery under general anesthesia, requiring Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V) insertion through the right internal jugular vein. Exclusion Criteria: A change in the mediastinal structure from previous neck surgery,thoracic surgery or cardiac surgery Extracardiac vascular anomaly Anatomical abnormality in neck and thorax Refusal to enrol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V)|Swan-Ganz CCOmbo V insertion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The distance | The distance between the insertion point and the junction between right atrium and superior vena cava | After insertion of the Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V) and during operation |
Knowledge and Awareness of Radiation Hazard in Health-care Personnel

Study Overview
=================
Brief Summary
-----------------
Knowledge and awareness of radiation hazard in health-care personnel; A Quaternary-care academic center study Aim: To determine knowledge and concerning about radiation hazard in anesthetic personnel and surgeon study decide: questionnaire based study to ask concerning and knowledge about radiation hazard

Official Title
-----------------
Knowledge and Awareness of Radiation Hazard in Health-care Personnel; A Quaternary-care Academic Center Study

Conditions
-----------------
Radiation Hazard

Intervention / Treatment
-----------------
* Other: Concerning and knowledge about radiation hazard questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Anesthetic personnel Surgeon: urology, orthopedic, cardiothoracic, neurosurgeon, general Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Concerning and knowledge about radiation hazard questionnaire|Concerning and knowledge about radiation hazard questionnaire to determine the concerning and knowledge of radiation hazard among surgeon and anesthesiologist|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| score of multiple choice question test about radiation hazard knowledge in anesthetic personnel and surgeon | score of MCQ test, good knowledge will be determine if more than 9 point of 15 point | 1 year |
Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox

Study Overview
=================
Brief Summary
-----------------
The investigatoris will carefully select cartilage-hair hypoplasia patients unexposed to varicella (VZV) and immunize patients in a controlled manner with VZV vaccine. Patients will be selected on the basis of disease severity and the degree of immunodeficiency (including CD4+ T-cell counts). Any potential complication of VZV immunization, such as rash, will be discussed with the patients/caregivers beforehand and acyclovir will be used to treat any VZV related symptoms, consistent with the current practices. The investigators will verify the development of immune response to vaccination by testing for VZV antibodies and cell-mediated immunity.

Official Title
-----------------
Immunodeficiency in Cartilage-hair Hypoplasia: Correlation With Pulmonary Disease, Infections and Malignancy

Conditions
-----------------
Cartilage-hair Hypoplasia

Intervention / Treatment
-----------------
* Biological: Varilrix


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: genetically confirmed cartilage-hair hypoplasia diagnosis age >12 months no history of chickenpox informed concent of the patient/caregiver. Exclusion Criteria: positive serum IgG for varicella zoster virus low CD4+ cell counts (<15% or <200 cells/mm3) clinical or laboratory signs of severe immunodeficiency ongoing intravenous or subcutaneous immunoglobulin treatment

Ages Eligible for Study
-----------------
Minimum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cartilage-hair hypoplasia (CHH)<br>Selected CHH patients will be vaccinated against varicella with Varilrix, one dose of 0,5 ml subcutaneously. If no response is documented to the first dose, the second dose of 0,5 ml can be administered. | Biological: Varilrix<br>* Vaccination against varicella in selected cartilage-hair hypoplasia patients<br>* Other names: ATC J07BK01;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Humoral response to vaccination |  | 4-6 weeks post-vaccination | 
| Cell-mediated response to vaccination |  | 4-6 wks post-vaccination | 
| Number and severity of adverse events to vaccination |  | 0-60 days |
Continuous Glucose Monitoring in New Mothers With Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
With appropriate day-time carbohydrate intake and insulin dose, the 24 hour glucose levels and prevalence of night-time hypoglycaemia are comparable in breastfeeding new mothers and formula feeding new mothers with type 1 diabetes at the second after delivery diabetes control compared with the first after delivery diabetes control at Steno Diabetes Center.

Official Title
-----------------
Continuous Glucose Monitoring During Breastfeeding or Formula Feeding in New Mothers With Type 1 Diabetes

Conditions
-----------------
Hypoglycemia, Breastfeeding

Intervention / Treatment
-----------------
* Device: Continuous glucose monitoring (CGM)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 45 years. Delivery of a single infant. Proficiency in Danish to read and understand the patient information sheet, questionnaires and to converse with the diabetes caregivers. Exclusion Criteria: A diagnosis with severe mental or psychiatric barriers or a concurrent disease on the decision of the principal investigator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| New mothers<br>New mothers with type 1 diabetes | Device: Continuous glucose monitoring (CGM)<br> <br> |
| Control group<br>Non-pregnant, non-breastfeeding women with type 1 diabetes matched for age and BMI | Device: Continuous glucose monitoring (CGM)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypoglycemia |  | Night-time 8 hours |
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

Study Overview
=================
Brief Summary
-----------------
The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long. If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer. The safety of LY900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs. How LY900003 is distributed and broken down by your body when it is given with carboplatin and gemcitabine. Whether LY900003 affects the way gemcitabine and carboplatin are distributed and broken down by your body.

Detailed Description
-----------------
Definition: The phase 2 study will provide important information regarding effects of LY900003 on safety and efficacy of patients treated with gemcitabine and carboplatin. LY900003 will be given at approximately 2 mg/kg/day for the first 14 days of a 21-day cycle. The dose and schedule for LY900003 administration are based on results of prior studies of LY900003 and are currently being used in other studies of LY900003. Gemcitabine will be administered on Days 1 and 8 at 1250 mg/m2 and carboplatin will be given on Day 1 at AUC 5.

Official Title
-----------------
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

Conditions
-----------------
Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms, Neoplasms, Lung

Intervention / Treatment
-----------------
* Drug: Gemcitabine
* Drug: Carboplatin
* Drug: LY900003


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Non-Small-Cell Lung Cancer. Stage IV or Stage IIIB disease. ECOG Performance Status of 0 or 1. Adequate organ function One unidimensionally measurable lesion. Exclusion Criteria: Prior therapy for NSCLC. Serious concomitant disorders. Untreated CNS metastases. Uncontrolled, active infection. Previous LY900003/ISIS trial participation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gemcitabine|nan|
|Drug: Carboplatin|nan|
|Drug: LY900003|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-Small-Cell Lung Cancer, Adenocarcinoma, Carcinoma Squamous, Adult Lung Cancer
What is the Effect of Prolapse Surgery on Voiding?

Study Overview
=================
Brief Summary
-----------------
The aim of our study is to examine the effect of prolapse surgery on voiding. Our study is the very first one to combine several innovative low-invasive and low-cost methods to analyse the amelioration or deterioration of voiding function after surgery for pelvic organ prolapse using 3D/4D translabial ultrasound, home-uroflowmetry and patient reported quality of life outcomes.

Official Title
-----------------
What is the Effect of Prolapse Surgery on Voiding?

Conditions
-----------------
Stress Urinary Incontinence, Overactive Bladder, Voiding Disorders, Urge Incontinence, Pelvic Organ Prolapse

Intervention / Treatment
-----------------
* Procedure: pelvic reconstructive surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥18 years Dutch, French or English- speaking women symptoms of pelvic organ prolapse preoperatively pelvic floor surgery. Exclusion Criteria: - history of neurological disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: pelvic reconstructive surgery|Pelvic reconstructive surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in lower urinary tract symptoms pre- postoperatively | Voiding diary | 1 year follow-up | 
| Change in lower urinary tract symptoms pre- postoperatively | Questionnaire: PFDI-20 | 1 year follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in clinical outcome measures | POP-Q | 1 year follow-up | 
| Change in clinical outcome measures | Transperineal ultrasound (TPUS) | 1 year follow-up | 
| Change in voiding | home-uroflowmetry | 1 year follow-up | 
| Change in QoL | Questionnaire: PFIQ-7 | 1 year follow-up | 
| Change in QoL | Questionnaire: PISQ-12 | 1 year follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pelvic Organ Prolapse, Surgery, 3D/4D imaging, urinary incontinence, voiding dysfunction, patient reported outcome